Tori Spelling shares her and her family’s journey with eczema and seborrheic dermatitis to encourage others to take control of their skin healthZORYVE® (roflumilast) is the #1 prescribed branded topical therapy for three major inflammatory skin conditions combined – eczema, plaque psoriasis, and seborrheic dermatitis WESTLAKE VILLAGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovatio ...

Bristol-Myers Squibb Company (NYSE:BMY) Q3 2025 Earnings Call October 30, 2025 08:00 AM ET Company ParticipantsAkash Tewari - Global Head of Biopharmaceutical ResearchChris Schott - Managing DirectorChuck Triano - SVP and Head of Investor RelationsMohit Bansal - Managing Director and Co-Head of Therapeutics ResearchCristian Massacesi - Chief Medical Officer and Head of Global Drug DevelopmentChris Boerner - Board Chair and CEOAdam Lenkowsky - Chief Commercialization OfficerCarter Gould - Biopharma Equity Re ...

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that late-breaking data demonstrating durable clinical activity of AgenT-797, allo-INKTs, in advanced solid tumors will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 7–9, 2025, in National Harb ...

BREAKING: Futures Mixed After Trump, Xi MeetAlnylam easily beat Wall Street's third-quarter forecasts on the back of its biggest moneymaker, Amvuttra. Alnylam stock, which has already doubled in 2025, could get a boost from the results.Amvuttra treats forms of transthyretin amyloidosis, a condition in which abnormal protein builds up on the organs. The Food and Drug Administration first approved Alnylam Pharmaceuticals' (ALNY) drug for patients with neuropathy in June 2022. This March, the agency signed off ...

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s third quarter 2025 financial results on Thursday, November 6, 2025, before the open of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company fou ...

THE WOODLANDS, Texas, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its third quarter 2025 financial results on Thursday, November 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s website at ht ...

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Nanomedicine Innovations Transforming Oncology Drug De ...

Financial Performance - Total revenue increased by 3% year-over-year to $2.53 billion in Q3 2025[59, 61, 64] - Launch products revenue grew 67% year-over-year, reaching $257 million in Q3 2025[19, 59] - GAAP diluted EPS increased by 19% year-over-year to $3.17, while Non-GAAP diluted EPS increased by 18% year-over-year to $4.81[59, 64] - The company generated $1.23 billion of free cash flow in Q3 2025[59] Product Performance - LEQEMBI achieved $121 million in in-market sales, demonstrating sustained sequential global demand growth[19, 48] - SKYCLARYS revenue grew 30% year-over-year and is now available in 34 markets globally[19, 52] - ZURZUVAE revenue increased by over 150% year-over-year, with 80% of prescriptions for first-line therapy[19, 55] Pipeline Advancement - Litifilimab Phase 3 studies for SLE are fully enrolled, with data expected in H2 2026[19, 34, 41] - A Phase 1 study was initiated for BIIB142, an IRAK4 degrader for autoimmune diseases[19, 21, 34, 35] - The company expects 3-4 potential new INDs[34, 35] Financial Guidance - Full year 2025 Non-GAAP diluted EPS is expected to be between $14.50 and $15.00[59] - Full year 2025 total revenue is expected to be approximately flat to increasing 1% at constant currency[59, 74] - The company expects to deliver $1 billion gross savings / $800 million net savings as part of the "Fit for Growth" initiative by the end of 2025[24, 79]

MIAMI, FL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, announced today the pricing of an underwritten public offering of (i) 1,400,000 shares of its common stock, (ii) pre-funded warrants to purchase up to 7,000,000 shares of its common stock, and (iii) accompanying Series A warrants to purchase up to 8,400,000 shares of common stock and a ...

Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2ZORYVE cream 0.05% provides rapid clearance of atopic dermatitisZORYVE can be used anywhere on the body for any duration and is not a steroidAtopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children in the U.S. WESTLAKE VILLAGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceu ...